Rosiglitazone and AS601245 decrease cell adhesion and migration through modulation of specific gene expression in human colon cancer cells

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Cerbone, Angelo ^a   Toaldo, Cristina ^b   Minelli, Rosalba ^b   Ciamporcero, Eric ^b   Pizzimenti, Stefania ^b   Pettazzoni, Piergiorgio ^b   Roma, Guglielmo ^a   Dianzani, Mario Umberto ^b   Ullio, Chiara ^b   Ferretti, Carlo ^b   Dianzani, Chiara ^b   Barrera, Giuseppina ^b  

^a Istituto di Ricerche Biomediche Antoine Marxer SpA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

(1,3 BENZOTHIAZOL 2 YL)[2 [2 (3 PYRIDINYL)ETHYLAMINO] 4 PYRIMIDINYL]ACETONITRILE; FIBRINOGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; CANCER CELL; CELL ADHESION; CELL MIGRATION; CELL STRAIN CACO 2; CELL STRAIN HT29; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; GENE EXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MODULATION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ACETONITRILES; BENZOTHIAZOLES; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLONIC NEOPLASMS; FIBRINOGEN; GENE EXPRESSION; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; THIAZOLIDINEDIONES;

EID: 84862990170     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040149     Document Type: Article

References (43)

1. Dubuquoy L, Rousseaux C, Thuru X, Peyrin-Biroulet L, Romano O, et al. (2006) PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 55: 1341-1349.
2. Tontonoz P, Hu E, Spiegelman BM, (1995) Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Curr Opin Genet Dev 5: 571-576.
3. Barrera G, Toaldo C, Pizzimenti S, Cerbone A, Pettazzoni P, et al. (2008) The Role of PPAR Ligands in Controlling Growth-Related Gene Expression and their Interaction with Lipoperoxidation Products. PPAR Res 2008: 524671.
4. Forman BM, Chen J, Evans RM, (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A 94: 4312-4317.
5. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, et al. (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270: 12953-12956.
6. Lehrke M, Lazar MA, (2005) The many faces of PPARgamma. Cell 123: 993-999.
7. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA, (1997) Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272: 3406-3410.
8. Theocharis S, Giaginis C, Parasi A, Margeli A, Kakisis J, et al. (2007) Expression of peroxisome proliferator-activated receptor-gamma in colon cancer: correlation with histopathological parameters, cell cycle-related molecules, and patients' survival. Dig Dis Sci 52: 2305-2311.
9. Ogino S, Shima K, Baba Y, Nosho K, Irahara K, et al. (2009) Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis. Gastroenterology 136: 1242-1250.
10. Jackson L, Wahli W, Michalik L, Watson SA, Morris T, et al. (2003) Potential role for peroxisome proliferator activated receptor (PPAR) in preventing colon cancer. Gut 52: 1317-1322.
11. McAlpine CA, Barak Y, Matise I, Cormier RT, (2006) Intestinal-specific PPARgamma deficiency enhances tumorigenesis in ApcMin/+ mice. Int J Cancer 119: 2339-2346.
12. Yoshizumi T, Ohta T, Ninomiya I, Terada I, Fushida S, et al. (2004) Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects. Int J Oncol 25: 631-639.
13. Chintharlapalli S, Papineni S, Safe S, (2006) 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes inhibit colon cancer cell and tumor growth through PPARgamma-dependent and PPARgamma-independent pathways. Mol Cancer Ther 5: 1362-1370.
14. Marin HE, Peraza MA, Billin AN, Willson TM, Ward JM, et al. (2006) Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis. Cancer Res 66: 4394-4401.
15. Chacko BK, Scott DW, Chandler RT, Patel RP, (2011) Endothelial surface N-glycans mediate monocyte adhesion and are targets for anti-inflammatory effects of peroxisome proliferator-activated receptor γ ligands. J Biol Chem 286: 38738-38747.
16. Nakajima A, Tomimoto A, Fujita K, Sugiyama M, Takahashi H, et al. (2008) Inhibition of peroxisome proliferator-activated receptor gamma activity suppresses pancreatic cancer cell motility. Cancer Sci 99: 1892-1900.
17. Cimini A, Cristiano L, Colafarina S, Benedetti E, Di Loreto S, et al. (2005) PPARgamma-dependent effects of conjugated linoleic acid on the human glioblastoma cell line (ADF). Int J Cancer 117: 923-933.
18. Diradourian C, Girard J, Pegorier JP, (2005) Phosphorylation of PPARs: from molecular characterization to physiological relevance. Biochimie 87: 33-38.
19. Genini D, Catapano CV, (2006) Control of peroxisome proliferator-activated receptor fate by the ubiquitinproteasome system. J Recept Signal Transduct Res 26: 679-692.
20. Yamashita D, Yamaguchi T, Shimizu M, Nakata N, Hirose F, et al. (2004) The transactivating function of peroxisome proliferator-activated receptor gamma is negatively regulated by SUMO conjugation in the amino-terminal domain. Genes Cells 9: 1017-1029.
21. Burgermeister E, Chuderland D, Hanoch T, Meyer M, Liscovitch M, et al. (2007) Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor gamma. Mol Cell Biol 27: 803-817.
22. Burgermeister E, Seger R, (2007) MAPK kinases as nucleo-cytoplasmic shuttles for PPARgamma. Cell Cycle 6: 1539-1548.
23. Camp HS, Tafuri SR, Leff T, (1999) c-Jun N-terminal kinase phosphorylates peroxisome proliferator-activated receptor-gamma1 and negatively regulates its transcriptional activity. Endocrinology 140: 392-397.
24. Ferrandi C, Ballerio R, Gaillard P, Giachetti C, Carboni S, et al. (2004) Inhibition of c-Jun N-terminal kinase decreases cardiomyocyte apoptosis and infarct size after myocardial ischemia and reperfusion in anaesthetized rats. Br J Pharmacol 142: 953-960.
25. Jaffe EA, Nachman RL, Becker CG, Minick CR, (1973) Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria J Clin Invest 52: 2745-2756.
26. Dianzani C, Collino M, Lombardi G, Garbarino G, Fantozzi R, (2003) Substance P increases neutrophil adhesion to human umbilical vein endothelial cells. Br J Pharmacol 139: 1103-1110.
27. Lemay DG, Hwang DH, (2006) Genome-wide identification of peroxisome proliferator response elements using integrated computational genomics. J Lipid Res 47: 1583-1587.
28. Reddy RC, Narala VR, Keshamouni VG, Milam JE, Newstead MW, et al. (2008) Sepsis-induced inhibition of neutrophil chemotaxis is mediated by activation of peroxisome proliferator-activated receptor-{gamma}. Blood 112: 4250-4258.
29. Staton CA, Brown NJ, Lewis CE, (2003) The role of fibrinogen and related fragments in tumour angiogenesis and metastasis. Expert Opin Biol Ther 3: 1105-1120.
30. Farnesi-de-Assunção TS, Alves CF, Carregaro V, de OliveiraJR, da Silva CA, et al. (2012) PPAR-γ agonists, mainly 15d-PGJ(2), reduce eosinophil recruitment following allergen challenge. Cell Immunol 273: 23-29.
31. Carter JC, Church FC, (2011) Peroxisome Proliferator-Activated Receptor-γ Ligands Alter Breast Cancer Cell Motility through Modulation of the Plasminogen Activator System. J Oncol 2011: 594258.
32. Kaoud TS, Mitra S, Lee S, Taliaferro J, Cantrell M, et al. (2011) Development of JNK2-selective peptide inhibitors that inhibit breast cancer cell migration. ACS Chem Biol 6: 658-666.
33. Hsu HH, Hu WS, Lin YM, Kuo WW, Chen LM, et al. (2011) JNK suppression is essential for 17β-Estradiol inhibits prostaglandin E2-Induced uPA and MMP-9 expressions and cell migration in human LoVo colon cancer cells. J Biomed Sci 18: 61.
34. ten Klooster JP, Jaffer ZM, Chernoff J, Hordijk PL, (2006) Targeting and activation of Rac1 are mediated by the exchange factor beta-Pix. J Cell Biol 172: 759-769.
35. Koh SH, Huh YM, Noh MY, Kim HY, Kim KS, et al. (2011) β-PIX is critical for transplanted mesenchymal stromal cell migration. Stem Cells Dev; in press.
36. Karin M, Herschman HR, (1979) Dexamethasone stimulation of metallothionein synthesis in HeLa cell cultures. Science 204: 176-177.
37. Summer KH, Klein D, de Ruiter N, Abel J, (1989) Metallothionein induction by nonsteroidal antiinflammatory drugs. Biol Trace Elem Res 21: 165-169.
38. Atrian S, Blindauer CA, Horst Lillig C, Berndt C, Hidalgo J, et al. (2009) Metallothioneins and Related Chelators. Cambridge: RSC Publishing.
39. Kumari MV, Hiramatsu M, Ebadi M, (1998) Free radical scavenging actions of metallothionein isoforms I and II. Free Radic Res 29: 93-101.
40. Pedersen MO, Larsen A, Stoltenberg M, Penkowa M, (2009) The role of metallothionein in oncogenesis and cancer prognosis. Prog Histochem Cytochem 44: 29-64.
41. Janssen AM, van Duijn W, Kubben FJ, Griffioen G, Lamers CB, et al. (2002) Prognostic significance of metallothionein in human gastrointestinal cancer. Clin Cancer Res 8: 1889-1896.
42. Straus DS, Glass CK, (2007) Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 28: 551-558.
43. Takayama T, Goji T, Taniguchi T, Inoue A, (2009) Chemoprevention of colorectal cancer-experimental and clinical aspects. J Med Invest 56: 1-5.